Genetics of Amyotrophic Lateral Sclerosis

Devil, M; Andersen, P. M.; Bosch, Ludo Van Den; Robberecht, Wim

doi:10.5772/31304

Search citation statements

Order By: Relevance

Paper Sections

Select...

More Update On Als1

Role Of Vegf In Als1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2014

2016

Publication Types

Select...

Book1

Article1

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(2 citation statements)

References 342 publications

(245 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, most of the genetic variability underlying ALS remains to be identified. The use of deep-sequencing techniques and functional research will be needed to further broaden our understanding of ALS pathogenesis [84].…”

Section: More Update On Alsmentioning

confidence: 99%

Introductory Chapter: Introduction to Update in Amyotrophic Lateral Sclerosis and Review of this Condition in Sportsmen

Foyaca-Sibat¹,

Valdés²

2016

Update on Amyotrophic Lateral Sclerosis

View full text Add to dashboard Cite

Section: More Update On Alsmentioning

confidence: 99%

Introductory Chapter: Introduction to Update in Amyotrophic Lateral Sclerosis and Review of this Condition in Sportsmen

Foyaca-Sibat¹,

Valdés²

2016

Update on Amyotrophic Lateral Sclerosis

View full text Add to dashboard Cite

“…Several clinical studies point to the involvement of VEGF in ALS. However, clinical reports failed to identify any specific VEGF mutation [ 40 , 223 – 225 ]. A study based on Swedish, English, Belgian, Russian, and American patients displayed an association between 2 haplotypes determined by 3 single-nucleotide polymorphisms (SNPS) −2.578 C/A, −1.154 L/C, and −634 G/C—in the VEGF upstream promoter/leader sequence of the VEGF gene with an increased risk of ALS [ 40 , 226 – 228 ].…”

Section: Role Of Vegf In Alsmentioning

confidence: 99%

Roles of Vascular Endothelial Growth Factor in Amyotrophic Lateral Sclerosis

Pronto-Laborinho

Pinto

Carvalho

2014

BioMed Research International

View full text Add to dashboard Cite

Amyotrophic lateral sclerosis (ALS) is a fatal devastating neurodegenerative disorder, involving progressive degeneration of motor neurons in spinal cord, brainstem, and motor cortex. Riluzole is the only drug approved in ALS but it only confers a modest improvement in survival. In spite of a high number of clinical trials no other drug has proved effectiveness. Recent studies support that vascular endothelial growth factor (VEGF), originally described as a key angiogenic factor, also plays a key role in the nervous system, including neurogenesis, neuronal survival, neuronal migration, and axon guidance. VEGF has been used in exploratory clinical studies with promising results in ALS and other neurological disorders. Although VEGF is a very promising compound, translating the basic science breakthroughs into clinical practice is the major challenge ahead. VEGF-B, presenting a single safety profile, protects motor neurons from degeneration in ALS animal models and, therefore, it will be particularly interesting to test its effects in ALS patients. In the present paper the authors make a brief description of the molecular properties of VEGF and its receptors and review its different features and therapeutic potential in the nervous system/neurodegenerative disease, particularly in ALS.

show abstract

Genetics of Amyotrophic Lateral Sclerosis

Cited by 2 publications

References 342 publications

Introductory Chapter: Introduction to Update in Amyotrophic Lateral Sclerosis and Review of this Condition in Sportsmen

Introductory Chapter: Introduction to Update in Amyotrophic Lateral Sclerosis and Review of this Condition in Sportsmen

Roles of Vascular Endothelial Growth Factor in Amyotrophic Lateral Sclerosis

Contact Info

Product

Resources

About